Activatable Matrix-Degrading Enzyme for Controlled ECM Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ECM-mediated diseases, such as collagen-mediated conditions, often rely on invasive procedures like surgery, and collagenase therapy is limited by prolonged activity and side effects, necessitating alternative methods for controlled matrix degradation.
Innovation Solution
Administration of an activatable matrix-degrading enzyme (AMDE) and an activator, which are inactive or partially inactive in the ECM, allowing for temporary activation upon introduction of the activator to achieve controlled degradation of ECM components, thereby treating diseases like cellulite, Dupuytren's disease, and Peyronie's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If collagenase is administered to treat ECM-mediated conditions, then collagen degradation is achieved, but the prolonged activity causes side effects and limits dosages
Solution Approach 1:
The enzyme is administered in an inactive zymogen form beforehand, which prevents premature degradation of ECM. The activation occurs only after the enzyme reaches the target site and is exposed to specific activating conditions (such as acidic pH or specific proteases), ensuring that the degradation action is timed appropriately and localized to the treatment site.
Solution Approach 2:
The patent utilizes changes in environmental parameters (such as pH levels, presence of specific ions, or proteolytic conditions) to control enzyme activation. The enzyme remains inactive under physiological conditions but becomes active when exposed to specific parameter changes at the target site, thereby controlling the duration and location of enzyme activity to minimize side effects.
2Reliability
If surgery or invasive procedures are used to treat ECM-mediated diseases, then effective treatment is achieved, but the invasiveness increases patient risk and recovery time
Solution Approach 1:
The patent replaces mechanical surgical interventions with a biochemical approach. Instead of physically removing or cutting ECM tissue through surgery, the treatment uses enzymatic degradation to break down collagen and other ECM components chemically. This substitution of mechanical action with biochemical action reduces invasiveness while maintaining treatment effectiveness.
3Productivity
If higher dosages of collagenase are administered to overcome prolonged activity limitations, then treatment coverage is improved, but side effects increase
Solution Approach 1:
By administering the enzyme in an inactive zymogen form, the patent enables the safe administration of higher dosages without immediate harmful effects. The inactive enzyme can be distributed more extensively throughout the target tissue without causing premature degradation or side effects. Activation occurs later at the target site, providing both wider coverage and controlled activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables targeted and temporary activation of matrix-degrading enzymes, reducing side effects and providing a less invasive treatment option for ECM-mediated conditions by controlling the duration of enzyme activity, effectively addressing the limitations of existing therapies.
Implementation Method 1
Collagenase, an enzyme active at neutral pH that degrades collagen
Implementation Method 2
the AMDE is selected to be an enzyme that is substantially inactive at neutral pH... the activator provides an acidic pH activating condition for the enzyme such that the AMDE is active
Data Source
AI summary
Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.